Internal Medicine, Hematology & Oncology · Birmingham, AL
NPI
1033559430
Since 2013
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2728 10th Ave S Ste 200
Birmingham, AL, 35205
Phone (205) 939-7880
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.8M
156,585 services
Medicare patients, 2024
306
Average age 75
Drug cost, 2024
$4.7M
1,819 prescriptions
Company payments, 2025
$4,020
From 53 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Carter L Capra was code J9271 (injection, pembrolizumab, 1 mg), 21,200 times for 14 patients. In total Carter L Capra billed 156,585 services in 119 codes, and Medicare paid $3.8M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-07-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 21,200 | 14 | $44.67 | $947K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 12,750 | 14 | $0.11 | $1,463 |
| J1556 Injection, immune globulin (bivigam), 500 mg | Office | 10,860 | 19 | $57.88 | $629K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,344 | 42 | $0.09 | $383 |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 2,700 | 18 | $15.85 | $43K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,040 | 26 | $0.71 | $1,439 |
| J0897 Injection, denosumab, 1 mg | Office | 1,980 | 11 | $20.39 | $40K |
| 36415 Venipuncture Blood Collection | Office | 813 | 252 | $8.60 | $6,993 |
| 99214 Office E&M - Established | Office | 713 | 180 | $87.25 | $62K |
| 96367 Intravenous Infusion, Hydration | Office | 634 | 46 | $19.12 | $12K |
| 96413 Chemotherapy Administration | Office | 432 | 58 | $85.49 | $37K |
| J9045 Injection, carboplatin, 50 mg | Office | 387 | 11 | $2.84 | $1,101 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 386 | 193 | $11.59 | $4,476 |
| 96375 Injection Administration | Office | 260 | 39 | $10.04 | $2,611 |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 250 | 16 | $0.24 | $60.79 |
By year: 2022 $2.7M for 162,479 services; 2023 $2.7M for 156,102 services; 2024 $3.8M for 156,585 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 813 | 252 | $8.60 | $6,993 |
Medicare prescription drug claims, 2024
In 2024, the drug Carter L Capra prescribed most often to Medicare patients was Letrozole, with 166 prescriptions and refills. In total Carter L Capra wrote 1,819 Medicare prescriptions that cost $4.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Letrozole Generic | 166 | 338 | 38 | $3,900 |
| Ondansetron Odt Ondansetron | 133 | 133 | 72 | $3,420 |
| Hydroxyurea Generic | 118 | 260 | 24 | $4,573 |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 113 | 113 | 31 | $2,005 |
| Revlimid Lenalidomide | 72 | 72 | Under 11 | $1.2M |
| Duloxetine Hcl Generic | 55 | 85 | 15 | $869 |
| Promethazine Hcl Generic | 53 | 53 | 33 | $488 |
| Acyclovir Generic | 53 | 63 | Under 11 | $461 |
| Lenalidomide Generic | 50 | 50 | Under 11 | $578K |
| Ibrance Palbociclib | 46 | 46 | Under 11 | $713K |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 45 | 45 | 15 | $804 |
| Furosemide Generic | 45 | 54 | 17 | $153 |
| Gabapentin Generic | 44 | 48 | 11 | $930 |
| Eliquis Apixaban | 41 | 51 | Under 11 | $29K |
| Potassium Chloride Generic | 40 | 48 | 18 | $1,701 |
Brand drugs: 330 claims; generic drugs: 1,489 claims; opioid claims: 220.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Carter L Capra $4,020 ($4,020 in general payments such as food, travel and fees) from 53 companies. The largest payer was Novartis Pharmaceuticals Corporation with $379.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 16 | $379 |
| AstraZeneca Pharmaceuticals LP AZN | 11 | $262 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 11 | $241 |
| Celgene Corporation BMY | 9 | $180 |
| Stemline Therapeutics Inc. | 8 | $169 |
| Immunocore Limited IMCR | 3 | $168 |
| Daiichi Sankyo Inc. 4568.T | 7 | $159 |
| Sobi, Inc SOBI.ST | 6 | $154 |
| Abbvie Inc. ABBV | 11 | $152 |
| BeOne Medicines USA, Inc. ONC | 8 | $144 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.